Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Host genotype is associated with selective colonization of human fecal microbiota in NCG and SGM3 mice: implications for microbiota-based therapies.

Bioscience of microbiota, food and health·2026
Same author

K<sub>3</sub>Yb<sub>2</sub>(BO<sub>3</sub>)<sub>3</sub> and Rb<sub>3</sub>Yb<sub>2</sub>(BO<sub>3</sub>)<sub>3</sub>: Two Rare-Earth Borate Ultraviolet Nonlinear Optical Crystals.

Inorganic chemistry·2026
Same author

Author Correction: BRIT1/MCPH1 links chromatin remodelling to DNA damage response.

Nature cell biology·2026
Same author

Modulation of the Mechanosensory Matrisome by Serotonergic Signaling.

Results and problems in cell differentiation·2026
Same author

Validation of a rat parastomal hernia model for evaluating mesh biocompatibility and repair outcomes.

Hernia : the journal of hernias and abdominal wall surgery·2026
Same author

A[A<sub>6</sub>Ch][Si<sub>12</sub>P<sub>20</sub>] (A = Sr, Ba; Ch = S, Se, Te): achieving a wide band gap in pnictides by constructing [A<sub>6</sub>Ch] octahedral ionic units.

Chemical science·2026

Related Experiment Video

Updated: Mar 6, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K

Identifying Cell Cycle Modulators That Selectively Target ARID1A Deficiency Using High-Throughput Image-Based

Lihong Zhang1,2, Jianfeng Shen2, Yuping Yin2,3

  • 11 Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.

SLAS Discovery : Advancing Life Sciences R & D
|March 16, 2017
PubMed
Summary
This summary is machine-generated.

Researchers identified new drug candidates to treat ARID1A-mutant cancers by screening compounds that target cell cycle regulation in ARID1A-deficient cells. This approach utilizes fluorescent ubiquitination-based cell cycle indicators (FUCCI) for high-throughput screening.

Keywords:
ARID1AFUCCIcell cycle modulatorhigh-throughput drug screening

More Related Videos

Generation and Isolation of Cell Cycle-arrested Cells with Complex Karyotypes
05:22

Generation and Isolation of Cell Cycle-arrested Cells with Complex Karyotypes

Published on: April 13, 2018

11.1K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.9K

Related Experiment Videos

Last Updated: Mar 6, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K
Generation and Isolation of Cell Cycle-arrested Cells with Complex Karyotypes
05:22

Generation and Isolation of Cell Cycle-arrested Cells with Complex Karyotypes

Published on: April 13, 2018

11.1K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.9K

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Research

Background:

  • ARID1A, a key component of the SWI/SNF chromatin remodeling complex, is frequently mutated in human cancers and regulates gene transcription.
  • ARID1A deficiency impacts DNA damage response and cell cycle checkpoint activation, suggesting potential therapeutic vulnerabilities.
  • Targeted therapies for ARID1A-mutant tumors are currently lacking.

Purpose of the Study:

  • To develop a novel screening method for identifying therapeutic agents targeting ARID1A-mutant cancer cells.
  • To discover chemical compounds that selectively modulate cell cycle progression in ARID1A-deficient cancer cells.

Main Methods:

  • Development of a high-throughput screening assay utilizing fluorescent ubiquitination-based cell cycle indicators (FUCCI).
  • Screening of 2,643 chemical compounds to identify modulators of cell cycle transition in ARID1A-deficient cells.

Main Results:

  • Identification of six chemical agents that selectively modulate the cell cycle in ARID1A-deficient cancer cells.
  • Demonstration of FUCCI-based screening as an effective method for discovering targeted cancer therapeutics.

Conclusions:

  • The identified chemical modulators show potential for developing novel therapeutics for ARID1A-mutant cancers.
  • FUCCI cell-based high-content screening is a powerful platform applicable to multigenotypic screening for targeted cancer therapies.